Methylsulfonylmethane / NRF2 Cancer Research Results

MSM, Methylsulfonylmethane: Click to Expand ⟱
Features:
MSM (Methylsulfonylmethane) is a naturally occurring organosulfur compound often used as a dietary supplement for its anti-inflammatory and antioxidant effects. While most well-known for joint health.
-MSM is actually a metabolite of DMSO (dimethyl sulfoxide) 
-Generally Recognized as Safe     Possible Interactions: aspirin, warfarin, NSAIDS

-Supplement dosage: 500mg 2-3times/day


-Anti-inflammatory: ↓NF-κB, ↓COX-2 and iNOS
-↓STAT3
-↓Cyclin D1 and CDK4, halting cell cycle progression.
-↓MMP-2, MMP-9, VEGF limiting invasion.

Methylsulfonylmethane (MSM) — Cancer-Oriented Time-Scale Flagged Pathway Table
Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 NF-κB inflammatory transcription NF-κB ↓; COX-2/cytokines ↓ (reported) Inflammation tone ↓ R, G Anti-inflammatory signaling One of the most consistent findings in MSM studies is suppression of NF-κB-linked inflammatory signaling.
2 STAT3 signaling STAT3 phosphorylation ↓ (reported) ↔ R, G Pro-survival pathway suppression STAT3 inhibition has been reported in some breast and other tumor models; relevance depends on tumor type.
3 PI3K / AKT pathway AKT signaling ↓ (reported; model-dependent) ↔ R, G Growth modulation Observed in certain cell lines; should be presented as context-dependent rather than universal.
4 ROS / redox modulation ROS ↓ (often); oxidative stress tone ↓ Oxidative injury ↓ P, R, G Redox buffering MSM is generally described as anti-oxidative/anti-inflammatory rather than pro-oxidant; not a ROS-amplifying therapy.
5 Apoptosis induction Caspases ↑; Bax ↑; Bcl-2 ↓ (reported) ↔ G Cell death signaling Apoptotic effects reported in vitro; usually downstream of inflammatory and survival pathway suppression.
6 Cell-cycle regulation Cell-cycle arrest ↑ (reported) ↔ G Cytostasis Observed in some cancer cell systems; mechanism linked to signaling changes.
7 Migration / invasion (MMPs) MMP expression ↓; migration ↓ (reported) ↔ G Anti-invasive phenotype Reduction in metastasis markers reported in certain preclinical models.
8 ER stress modulation Stress signaling modulation (context-dependent) Proteostasis support R, G Stress pathway modulation Less consistent than NF-κB effects; should be kept qualified.
9 Chemo-/radiation interaction (theoretical) May reduce inflammatory toxicity; may blunt ROS-based therapies Normal tissue protection possible G Adjunct positioning Because MSM is anti-oxidative/anti-inflammatory, positioning with strong pro-oxidant therapies should be considered carefully.
10 Translation constraint Human anti-cancer efficacy not established Generally well tolerated in common supplement ranges — Evidence limitation Evidence base is largely preclinical; clinical oncology data are limited.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (early redox/inflammatory signaling shifts)
  • R: 30 min–3 hr (NF-κB / STAT3 pathway modulation)
  • G: >3 hr (cell-cycle, apoptosis, invasion phenotype changes)


For Alzheimer's (AD):
Methylsulfonylmethane (MSM) in neurobiology is primarily framed as an anti-inflammatory and redox-buffering molecule, not a direct amyloid-clearing or tau-targeting drug. Evidence is largely preclinical (cell + animal models). Position it as a neuroinflammation and oxidative stress modulator.
-Anti-inflammatory: ↓TNF-α, IL-1β, IL-6 
-↓ROS, ↑GSH, ↓NO
-may reduce Aβ plaque burden and tau hyperphosphorylation indirectly
-improves memory in rodents

Methylsulfonylmethane (MSM) — Alzheimer’s Disease (AD) Time-Scale Flagged Pathway Table
Rank Pathway / Axis AD / Brain Context TSF Primary Effect Notes / Interpretation
1 Neuroinflammation (NF-κB / cytokine signaling) Microglial activation ↓; IL-1β/TNF-α ↓ (reported) R, G Anti-inflammatory modulation MSM’s most consistent neuro-relevant signal is suppression of NF-κB-driven inflammatory tone, which is implicated in AD progression.
2 Oxidative stress / redox buffering Lipid peroxidation ↓; ROS tone ↓ (reported) R, G Neuroprotection (stress buffering) MSM is generally described as antioxidant/anti-inflammatory rather than pro-oxidant; may help mitigate oxidative injury.
3 Mitochondrial function support Mitochondrial stress ↓ (context-dependent) R, G Bioenergetic stabilization Indirect support through reduced oxidative and inflammatory burden; not a primary mitochondrial activator.
4 ER stress / proteostasis modulation UPR signaling ↓ (reported in stress models) R, G Proteostasis buffering ER stress is relevant in AD pathology; MSM may attenuate stress signaling in some models.
5 Calcium homeostasis modulation Excitotoxic stress ↓ (indirect) P, R Signal stabilization Primarily indirect via inflammatory and oxidative stress reduction.
6 Aβ pathology (direct evidence) Limited direct evidence of amyloid reduction G Indirect modulation If effects occur, they are likely secondary to reduced oxidative stress and inflammation rather than direct amyloid targeting.
7 Tau phosphorylation Limited direct mechanistic evidence G Indirect modulation No strong mechanistic evidence that MSM directly modulates tau kinases; effects likely indirect.
8 Blood–brain barrier (BBB) considerations CNS exposure plausible but not strongly quantified R PK consideration Systemic exposure is good; CNS-specific pharmacokinetics are less clearly defined.
9 Cognitive outcome evidence Limited direct human AD trial data — Translation constraint Evidence base is largely mechanistic/preclinical; clinical AD efficacy not established.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (early redox/inflammatory signaling shifts)
  • R: 30 min–3 hr (microglial signaling + oxidative stress modulation)
  • G: >3 hr (phenotype-level neuroprotection effects)
NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
3847- MSM,    Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement
- Review, Arthritis, NA
*Inflam↓, *Pain↓, *ROS↓, *antiOx↑, *Dose↝, *Half-Life↝, *NF-kB↓, *IL1↓, *IL6↓, *TNF-α↓, *iNOS↓, *COX2↓, *NLRP3↓, *NRF2↑, *STAT↓, *Cartilage↑, *eff↑, *eff↑, *GSH↑, *uricA↓, tumCV↓, TumCCA↑, necrosis↑, Apoptosis↑, VEGF↓, HSP90↓, IGF-1?,
3848- MSM,    Modulatory effect of methylsulfonylmethane against BPA/γ-radiation induced neurodegenerative alterations in rats: Influence of TREM-2/DAP-12/Syk pathway
- in-vitro, AD, NA
*ROS↓, *Inflam↓, *neuroP↑, *ER(estro)↑, *NRF2↑, *HO-1↑, *Trx1↑, *TXNIP↓, *MDA↓, *NOX↓, *GSH↑, *GPx↑, *SOD↑, *Catalase↑, *BDNF↑, *AChE↓, *p‑tau↓, *Aβ↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,   necrosis↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

HSP90↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1?, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 2,   HO-1↑, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 2,   SOD↑, 1,   Trx1↑, 1,   uricA↓, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

STAT↓, 1,  

Migration ⓘ

Cartilage↑, 1,   TXNIP↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

NOX↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 1,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

ER(estro)↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 2,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,   Pain↓, 1,  
Total Targets: 34

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:124  Target#:226  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page